Thoracic Oncology
Clinical research at Amphia Hospital includes non small cell lung cancer, with related interest in mesothelioma and thymoma, reflecting a focus on malignancies of the chest and pleura.
- Non small cell lung cancer
- Mesothelioma
- Thymoma
The sponsor’s research activity in this area is centred on treatment-related outcomes in patients receiving cancer therapy.
Haematological Toxicity
The hospital’s trial portfolio includes evaluation of haematological toxicity associated with anticancer treatment, with particular attention to blood-related adverse effects during therapy.
- Haematological toxicity
- Adverse events
- Supportive care
This area highlights interest in reducing treatment burden and monitoring safety in oncology patients.
Supportive Oncology
Research activity also extends to supportive oncology, with attention to measures intended to improve tolerability of cancer treatment and manage therapy-associated complications.
- Rescue therapy
- Treatment tolerability
- Therapy-related complications
Within this domain, the sponsor is engaged in clinical questions that address patient safety during active cancer care.
Folate-Related Intervention
Amphia Hospital’s funded research includes interest in folinic acid as part of a strategy to limit treatment-related toxicity, linking nutritional and pharmacologic support with oncology care.
- Folinic acid
- Pemetrexed
- Adverse event prevention
This focus connects medication safety with the management of side effects in patients receiving systemic cancer therapy.
